Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT04855656

Public ClinicalTrials.gov record NCT04855656. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

Study identification

NCT ID: NCT04855656
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Debiopharm International SA; Industry
Enrollment: 464 participants

Conditions and interventions

Conditions

Advanced Solid Tumor

Interventions

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 29, 2021
Primary completion: Nov 30, 2027
Completion: May 31, 2028
Last update posted: Aug 23, 2026

2021 – 2028

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 15

Facility	City	State	ZIP	Site status
# 1019, UCLA, Westwood Cancer Center	Los Angeles	California	90095	Completed
#1025, University of California San Francisco	San Francisco	California	94158	Recruiting
#1012, Yale	New Haven	Connecticut	06520	Recruiting
#1017, Mayo Clinic	Jacksonville	Florida	32224	Recruiting
#1002, Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
#1023, START Midwest	Grand Rapids	Michigan	49503	Recruiting
#1016, Mayo Clinic	Rochester	Minnesota	55902	Recruiting
#1011, Washington University	St Louis	Missouri	63130	Recruiting
#1032, Northwell Health Cancer Institute	New Hyde Park	New York	11042	Recruiting
#1008, Columbia University	New York	New York	10032	Completed
#1004, Memorial Sloan Kettering Cancer Institute	New York	New York	10065	Recruiting
#1010, University of Pennsylvania	Philadelphia	Pennsylvania	19104	Completed
#1007, Rhode Island Hospital	Providence	Rhode Island	02903	Recruiting
#1030, Women & Infants Hospital of Rhode Island	Providence	Rhode Island	02903	Recruiting
#1001, The University of Texas M.D. Anderson Cancer Center	Houston	Texas	77030	Recruiting
#1013, The University of Utah	Salt Lake City	Utah	84112	Recruiting
#1027, University of Virginia	Charlottesville	Virginia	22903	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04855656, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 23, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04855656 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →